東華大學圖書館 |

Genome Editing with Crispr/Cas9 to Study and Treat Primary Immune Regulatory Disorders.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Genome Editing with Crispr/Cas9 to Study and Treat Primary Immune Regulatory Disorders./
Author:	Lee, Esmond Yan Zhao.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
Description:	195 p.
Notes:	Source: Dissertations Abstracts International, Volume: 83-11, Section: B.
Contained By:	Dissertations Abstracts International83-11B.
Subject:	Infections. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29099820
ISBN:	9798426880788

Genome Editing with Crispr/Cas9 to Study and Treat Primary Immune Regulatory Disorders.
Lee, Esmond Yan Zhao.

Genome Editing with Crispr/Cas9 to Study and Treat Primary Immune Regulatory Disorders. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 195 p.

Source: Dissertations Abstracts International, Volume: 83-11, Section: B.

Thesis (Ph.D.)--Stanford University, 2021.

This item must not be sold to any third party vendors.

For those living with genetic disease, the advent of gene therapy represents an end to years of repeated treatment and daily disease management. Using gene editing tools, patient cells can be modified to provide long term therapeutic benefit that cures or mitigates disease. In particular, clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology allows us to make precise genetic changes to cells for therapeutic benefit. During CRISPR gene editing, single guide RNA (sgRNA) directs Cas9 nuclease to make a double-stranded cut to DNA at a precise location in the genome. A DNA repair cassette delivered by recombinant adeno-associated virus (rAAV) is then inserted at the cut site via homologous recombination. This repair cassette can be designed to contain a therapeutic gene which can be expressed at physiological levels, under the control of endogenous regulatory elements.Monogenic disorders of the blood and immune system are severe diseases with limited therapeutic options. While allogeneic hematopoietic stem cell transplantations (HSCT) have historically been used to treat blood and immune disorders, the rise of CRISPR/Cas9 technology has enabled us to modify a patient's own stem cells for autologous transplantation, thereby circumventing the challenges associated with rejection. Hematopoietic stem and progenitor cells (HSPCs) are particularly amenable to gene therapy because we can isolate, culture, and modify them ex vivo.This dissertation explores CRISPR/Cas9 based gene editing as a new therapeutic modality for two primary immune regulatory disorders caused by mutations in the FOXP3 and IL-10 genes, respectively. The goal of this therapeutic modality is to engraft gene edited patient HSPCs to enable healthy hematopoietic reconstitution, curing the disease. The gene editing strategy was validated through assaying the phenotype and function of edited primary T cells; the engraftment and differentiation potential of edited HSPCs were subsequently confirmed in the NSG-SGM3 humanized mouse model. Further, CRISPR/Cas9 knockout experiments elucidated the mechanisms of dysregulation in specific immune subsets, advancing our understanding of the role of FOXP3 and IL-10 in health and disease.Another aspect of bringing cell and gene therapies to the clinic is the complexity and cost of manufacturing. An understated factor that could expedite patient access to gene therapies is robust and cost-efficient manufacturing processes. The final segment of this dissertation applies a regression-based approach to understand key factors influencing gene editing frequencies in CD4+ T cells. Editing frequencies across varying guide and rAAV concentrations were linked to a cost of raw materials analysis model to provide information on the cost drivers of gene targeting and to predict cost-optimal editing conditions for cell therapy manufacturing.

ISBN: 9798426880788Subjects--Topical Terms:

1621997
Infections.

Genome Editing with Crispr/Cas9 to Study and Treat Primary Immune Regulatory Disorders.
LDR:04105nmm a2200373 4500 001 2352084
005 20221111121014.5
008 241004s2021 ||||||||||||||||| ||eng d
020 $a 9798426880788
035 $a (MiAaPQ)AAI29099820
035 $a (MiAaPQ)STANFORDkc729cs5093
035 $a AAI29099820
040 $a MiAaPQ $c MiAaPQ
100 1 $a Lee, Esmond Yan Zhao. $3 3691702
245 1 0 $a Genome Editing with Crispr/Cas9 to Study and Treat Primary Immune Regulatory Disorders.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 195 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-11, Section: B.
500 $a Advisor: Bacchetta, Rosa;Maltzman, Jonathan;Porteus, Matthew;Roncarolo, Maria Grazia;Wright, John.
502 $a Thesis (Ph.D.)--Stanford University, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a For those living with genetic disease, the advent of gene therapy represents an end to years of repeated treatment and daily disease management. Using gene editing tools, patient cells can be modified to provide long term therapeutic benefit that cures or mitigates disease. In particular, clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology allows us to make precise genetic changes to cells for therapeutic benefit. During CRISPR gene editing, single guide RNA (sgRNA) directs Cas9 nuclease to make a double-stranded cut to DNA at a precise location in the genome. A DNA repair cassette delivered by recombinant adeno-associated virus (rAAV) is then inserted at the cut site via homologous recombination. This repair cassette can be designed to contain a therapeutic gene which can be expressed at physiological levels, under the control of endogenous regulatory elements.Monogenic disorders of the blood and immune system are severe diseases with limited therapeutic options. While allogeneic hematopoietic stem cell transplantations (HSCT) have historically been used to treat blood and immune disorders, the rise of CRISPR/Cas9 technology has enabled us to modify a patient's own stem cells for autologous transplantation, thereby circumventing the challenges associated with rejection. Hematopoietic stem and progenitor cells (HSPCs) are particularly amenable to gene therapy because we can isolate, culture, and modify them ex vivo.This dissertation explores CRISPR/Cas9 based gene editing as a new therapeutic modality for two primary immune regulatory disorders caused by mutations in the FOXP3 and IL-10 genes, respectively. The goal of this therapeutic modality is to engraft gene edited patient HSPCs to enable healthy hematopoietic reconstitution, curing the disease. The gene editing strategy was validated through assaying the phenotype and function of edited primary T cells; the engraftment and differentiation potential of edited HSPCs were subsequently confirmed in the NSG-SGM3 humanized mouse model. Further, CRISPR/Cas9 knockout experiments elucidated the mechanisms of dysregulation in specific immune subsets, advancing our understanding of the role of FOXP3 and IL-10 in health and disease.Another aspect of bringing cell and gene therapies to the clinic is the complexity and cost of manufacturing. An understated factor that could expedite patient access to gene therapies is robust and cost-efficient manufacturing processes. The final segment of this dissertation applies a regression-based approach to understand key factors influencing gene editing frequencies in CD4+ T cells. Editing frequencies across varying guide and rAAV concentrations were linked to a cost of raw materials analysis model to provide information on the cost drivers of gene targeting and to predict cost-optimal editing conditions for cell therapy manufacturing.
590 $a School code: 0212.
650 4 $a Infections. $3 1621997
650 4 $a Gene therapy. $3 600619
650 4 $a Collaboration. $3 3556296
650 4 $a Genetic disorders. $3 750480
650 4 $a Mutation. $3 837917
650 4 $a Cytokines. $3 687114
650 4 $a Sickle cell disease. $3 3691703
650 4 $a Congenital diseases. $3 3682545
650 4 $a Genomes. $3 592593
650 4 $a Genotype & phenotype. $3 3561790
650 4 $a Cell cycle. $3 766119
650 4 $a Patients. $3 1961957
650 4 $a CRISPR. $3 3561750
650 4 $a Raw materials. $3 648907
650 4 $a Medicine. $3 641104
650 4 $a Regulation. $3 3561775
650 4 $a Christianity. $3 581949
650 4 $a Immune system. $3 689864
650 4 $a Medical research. $2 bicssc $3 1556686
650 4 $a Lymphocytes. $3 895384
650 4 $a Antigens. $3 700737
650 4 $a Vectors (Biology). $3 3691704
650 4 $a Biology. $3 522710
650 4 $a Cellular biology. $3 3172791
650 4 $a Genetics. $3 530508
650 4 $a Immunology. $3 611031
650 4 $a Religion. $3 516493
650 4 $a Therapy. $3 3343697
690 $a 0564
690 $a 0306
690 $a 0379
690 $a 0369
690 $a 0982
690 $a 0318
690 $a 0212
710 2 $a Stanford University. $3 754827
773 0 $t Dissertations Abstracts International $g 83-11B.
790 $a 0212
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29099820